Ecnoglutide (受体激动剂) is a novel long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It combines potent GLP-1 receptor activation with an optimized pharmacokinetic profile, offering effective glycemic control, significant weight reduction, and potential cardiovascular benefits with once-weekly dosing convenience.
受体激动剂是一种新型长效胰高血糖素样肽-1（GLP-1）受体激动剂，专为治疗2型糖尿病（T2DM）和肥胖症而设计。它结合强效GLP-1受体激活和优化的药代动力学特征，提供有效的血糖控制、显著的体重减轻和潜在的心血管获益，每周一次给药便捷。
CAS Number | 2459531-73-6 |
Molecular Formula | C187H288N50O62S |
Molecular Weight | 4225.68 g/mol |
Sequence | Long-acting GLP-1 analog with engineered fatty acid acylation for albumin binding and extended half-life |
Appearance | White to off-white lyophilized powder |
Solubility | Soluble in aqueous buffers (pH 7.0-8.0) |
Storage | Store at -20°C, protected from light and moisture |
Pharmacological Class | GLP-1 receptor agonist (incretin mimetic) |
Indication | Type 2 diabetes mellitus (T2DM); chronic weight management; cardiovascular risk reduction |
Administration Route | Subcutaneous (SC) injection once weekly |
Purity | >= 98.0% (by HPLC) |
产品卖点 / Product Highlights
特点 Feature | 说明 Description | 客户价值 Value |
Dual T2DM & Obesity Action 双重降糖减重作用 | Potent GLP-1 receptor agonist delivering robust HbA1c reduction (up to 1.5-2.0%) and clinically meaningful weight loss (10-15% body weight). 强效GLP-1受体激动剂，提供显著的糖化血红蛋白降低（高达1.5-2.0%）和具有临床意义的体重减轻（10-15%体重）。 | Addresses the largest and fastest-growing metabolic therapeutic market with dual revenue streams from diabetes and obesity indications. 瞄准最大且增长最快的代谢治疗市场，从糖尿病和肥胖适应症获得双重收入来源。 |
Once-Weekly Convenience 每周一次便捷性 | Fatty acid acylation technology enables albumin binding with plasma half-life of ~5-7 days, supporting weekly dosing. 脂肪酸酰化技术实现白蛋白结合，血浆半衰期约5-7天，支持每周给药。 | Superior patient adherence versus daily alternatives; aligns with current standard-of-care expectations in the GLP-1 market. 与每日给药替代品相比患者依从性更优；符合GLP-1市场中当前的护理标准期望。 |
Cardiovascular Benefit Potential 心血管获益潜力 | Emerging clinical data suggests significant reduction in MACE endpoints consistent with established GLP-1 agonist class effects. 新兴临床数据显示主要不良心血管事件（MACE）终点显著降低，与已确立的GLP-1激动剂类效应一致。 | CV outcome differentiation increasingly determines payer coverage and market access; strong competitive positioning. 心血管结局差异化越来越决定支付方覆盖和市场准入；具有强竞争定位。 |
Engineered Molecular Design 工程化分子设计 | Optimized peptide backbone with site-specific acylation for enhanced albumin affinity and reduced immunogenicity. 优化的肽骨架，通过位点特异性酰化增强白蛋白亲和力并降低免疫原性。 | Advanced molecular architecture provides improved stability and consistent pharmacokinetics across patient populations. 先进的分子结构在所有患者群体中提供改进的稳定性和一致的药代动力学。 |
Explosive Market Growth 市场爆发式增长 | The global GLP-1 agonist market is projected to exceed $50 billion by 2030, driven by obesity indication expansion. 全球GLP-1激动剂市场预计到2030年将超过500亿美元，由肥胖适应症扩展驱动。 | High-volume API demand from generic developers and emerging market manufacturers creates premium supply opportunities. 仿制药开发商和新兴市场制造商的高容量API需求创造优质供应机会。 |
Scalable GMP Manufacturing 可扩展GMP生产 | Multi-kilogram GMP manufacturing capacity with validated processes, full stability programs, and global regulatory documentation. 多公斤GMP生产能力，具有经验证的生产工艺、完整的稳定性项目和全球法规文件。 | Reliable commercial supply for Phase III through launch, with batch records suitable for US FDA, EMA, and NMPA filings. 从III期到上市的可靠商业供应，批记录适用于美国FDA、EMA和NMPA申报。 |
Full-Service API Partner 全服务API合作伙伴 | Integrated supply of Ecnoglutide API, reference standards, potency assays, and complete regulatory submission dossiers. 受体激动剂API、对照品、效价测定和完整法规申报文件的集成供应。 | End-to-end procurement simplifies supply chain management and accelerates time-to-market for formulation partners worldwide. 端到端采购简化供应链管理，加速全球制剂合作伙伴的上市时间。 |
